--- title: "Werewolf Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/280778663.md" datetime: "2026-03-27T11:09:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280778663.md) - [en](https://longbridge.com/en/news/280778663.md) - [zh-HK](https://longbridge.com/zh-HK/news/280778663.md) --- # Werewolf Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0 Revenue: As of FY2025 Q4, the actual value is USD 0. EPS: As of FY2025 Q4, the actual value is USD -0.2, beating the estimate of USD -0.345. ### Cash Position - As of December 31, 2025, cash and cash equivalents were $57.1 million, compared to $65.7 million as of September 30, 2025, and $111.0 million as of December 31, 2024. ### Operational Metrics #### Collaboration Revenue - For the fourth quarter of 2025, collaboration revenue was $0, consistent with the fourth quarter of 2024. - For the full year 2025, collaboration revenue was $0, a decrease from $1.9 million for the full year 2024. #### Research and Development Expenses - Research and development expenses were $6.9 million for the fourth quarter of 2025, a decrease from $15.7 million for the same period in 2024. - For the full year 2025, these expenses were $44.8 million, down from $56.4 million for the full year 2024. #### General and Administrative Expenses - General and administrative expenses were $2.5 million for the fourth quarter of 2025, compared to $4.6 million for the same period in 2024. - For the full year 2025, these expenses totaled $15.8 million, a reduction from $19.0 million for the full year 2024. #### Total Operating Expenses - Total operating expenses were $9.4 million for the fourth quarter of 2025, down from $20.3 million for the same period in 2024. - For the full year 2025, total operating expenses were $60.7 million, compared to $75.5 million for the full year 2024. #### Operating Loss - Operating loss was - $9.4 million for the fourth quarter of 2025, an improvement from - $20.3 million for the same period in 2024. - For the full year 2025, the operating loss was - $60.7 million, compared to - $73.6 million for the full year 2024. #### Other Income (Expense) - Other income was $1.0 million for the fourth quarter of 2025, compared to other expense of - $0.05 million for the same period in 2024. - For the full year 2025, other expense was - $0.15 million, compared to other income of $3.1 million for the full year 2024. #### Net Loss - Net loss was - $8.4 million for the fourth quarter of 2025, an improvement from - $20.4 million for the same period in 2024. - For the full year 2025, net loss was - $60.8 million, compared to - $70.5 million for the full year 2024. #### Net Loss Per Common Share (Basic) - Net loss per common share (basic) was - $0.17 for the fourth quarter of 2025, compared to - $0.46 for the same period in 2024. - For the full year 2025, net loss per common share (basic) was - $1.32, compared to - $1.63 for the full year 2024. #### Net Loss Per Common Share (Diluted) - Net loss per common share (diluted) was - $0.20 for the fourth quarter of 2025, compared to - $0.46 for the same period in 2024. - For the full year 2025, net loss per common share (diluted) was - $1.33, compared to - $1.63 for the full year 2024. #### Weighted-Average Common Shares Outstanding (Basic) - Weighted-average common shares outstanding (basic) were 48,425,423 for the fourth quarter of 2025, up from 44,478,140 for the same period in 2024. - For the full year 2025, these shares totaled 46,018,888, compared to 43,332,088 for the full year 2024. #### Weighted-Average Common Shares Outstanding (Diluted) - Weighted-average common shares outstanding (diluted) were 49,216,787 for the fourth quarter of 2025, up from 44,478,140 for the same period in 2024. - For the full year 2025, these shares totaled 46,810,252, compared to 43,859,664 for the full year 2024. ### Selected Consolidated Balance Sheet Data (as of December 31) - **Working Capital:** $22.4 million in 2025, down from $97.9 million in 2024. - **Total Assets:** $69.4 million in 2025, down from $126.9 million in 2024. - **Total Notes Payable, Net of Discount and Issuance Costs:** $28.2 million in 2025, up from $26.1 million in 2024. - **Total Stockholders’ Equity:** $24.8 million in 2025, down from $73.4 million in 2024. ### Outlook / Guidance Werewolf Therapeutics, Inc. anticipates its current cash and cash equivalents will be sufficient to fund operational expenses and capital requirements into the fourth quarter of 2026. The company is evaluating strategic alternatives to maximize stockholder value, including potential sale, merger, asset sale, licensing, or other transactions. However, there is no defined timeline or assurance of a specific outcome regarding these alternatives. ### Related Stocks - [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md) ## Related News & Research - [Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock](https://longbridge.com/en/news/287219594.md) - [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md) - [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md) - [Larimar Shareholders Approve Governance and Capital Structure Changes](https://longbridge.com/en/news/286968564.md) - [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md)